The basis for interindividual variation in the CYP1A2 gene expression is not fully understood and the known genetic polymorphisms in the gene provide no explanation. We investigated whether the CYP1A2 gene expression is regulated by DNA methylation and displays allele-specific expression (ASE) using 65 human livers. Forty-eight percent of the livers displayed ASE not associated to the CYP1A2 mRNA levels. The extent of DNA methylation of a CpG island including 17 CpG sites, close to the translation start site, inversely correlated with hepatic CYP1A2 mRNA levels (P ¼ 0.018). The methylation of two separate core CpG sites was strongly associated with the CYP1A2 mRNA levels (P ¼ 0.005) and ASE phenotype (P ¼ 0.01), respectively. The CYP1A2 expression in hepatoma B16A2 cells was strongly induced by treatment with 5-aza-2 0 -deoxycytidine. In conclusion, the CYP1A2 gene expression is influenced by the extent of DNA methylation and displays ASE, mechanisms contributing to the large interindividual differences in CYP1A2 gene expression.
Introduction
The human cytochrome P450 1A2 (CYP1A2) enzyme is expressed mainly in the liver and accounts for about 13% of the total P450 content in the liver. 1 It has an important function in the metabolism of caffeine as well as of several clinically important drugs such as clozapine, 2 phenacetin, 3 verapmil, 4 endogenous substrates such as melatonin, 5 estradiol, 6 and procarcinogenic substances including heterocyclic amines, arylamines and aflatoxin B1. 7, 8 The CYP1A2 gene shows large interindividual and interethnic differences in both mRNA expression level and enzyme activity. [8] [9] [10] The underlying causes for this variation are not known and could be caused by genetic, epigenetic or environmental factors. Indeed, CYP1A2 is genetically polymorphic with more than 16 variant alleles described so far (http://www.cypalleles.ki.se/cyp1a2.htm). However, the low frequency of the functionally different variant alleles in the populations and the results of several genotype-phenotype association studies indicate a limited function of CYP1A2 genetic polymorphism as a cause of interindividual variation in CYP1A2 gene expression or activity. 11, 12 In line of this research, we have found one allele CYP1A2*1K causing lower expression of the gene but it is present in Ethiopians 13 and almost absent in whites and Asians. 11, 12 The interethnic differences in CYP1A2 activity is important and by controlling for the effects of smoking, oral contraceptive use and genotype, we recently reported the presence of significant differences in enzyme activity between Swedish, Korean and Serbian populations, differences not explained by the known CYP1A2 single nucleotide polymorphisms (SNPs)/ haplotypes. 12, 14 Apart from genetic polymorphisms, phenotypic variations are governed by other factors affecting gene expression, such as gene cis-and trans-acting transcriptional components, alternative splicing, RNA stability, expression of regulatory RNAs and epigenetics such as histone modifications and DNA methylation. 15 Imprinted genes (parent of origin-specific gene expression in somatic cells) and genes subject to X chromosome inactivation display monoallelic expression. Differential gene expression between the two alleles or allele-specific expression (ASE) in nonimprinted genes is also common in the human genome. [16] [17] [18] [19] The degree of differences in the expression between the two alleles varies from individual to individual causing phenotypic variability. ASE reflects the presence of putative allelespecific cis-acting factors of either genetic or epigenetic origin. Consequently, ASE can be used as a promising quantitative phenotyping method for identifying cis-acting factors as well as epigenetic variation influencing gene expression because individuals heterozygous for cis-acting polymorphism show a different level of mRNA expression originating from one allele compared to the other. 16, 17, 20 The two major mechanisms for epigenetic modifications are DNA methylation and histone deacetylation, and interindividual variations in the degree of these mechanisms could form a basis for interindividual differences in gene expression. Epigenetic modifications and ASE in pharmacogenetic-related genes have been shown to affect expression and activity. ASE for the MDR1, CYP2D6 and CYP2C9 genes has been reported recently. 21 Hirota et al.
22
reported the occurrence of ASE in the CYP3A4 gene expression that correlated with the total CYP3A4 mRNA levels in liver but no clear association between gene methylation and total mRNA levels was found. Nakajima et al. 23 indicated a function of histone deacetylation and DNA methylation in cell-specific inducibility of the human CYP1 family. Tissue-specific variation in the degree of gene methylation in CYP2E1 gene is associated with CYP2E1 mRNA levels and enzyme activity that has been reported previously. 24 Furthermore, Hammons et al.
25
showed an association between interindividual variation in human hepatic CYP1A2 expression and degree of methylation of a CpG site (bp À2759) in the 5 0 -flanking region of the CYP1A2 gene, with hypermethylation correlated with decreased CYP1A2 expression. However, the CpG site investigated by Hammons et al. is not located within a CYP1A2 CpG island and is located far away from the transcription start site. Indeed, functional CpG islands typically occur at or near the transcription start site of genes 26 causing transcriptional repression by inhibition of binding of transcription factor.
While appreciating the existence of the wide interindividual variation in the constitutive CYP1A2 mRNA expression and enzyme activity, the underlying causes remain unclear. It is generally accepted that most of the known SNPs in the CYP1A2 gene and 5 0 -flanking regions do not determine the observed large interindividual variability in constitutive hepatic CYP1A2 mRNA expression and enzyme activity. 11 Identification of the molecular mechanism behind variation in CYP1A2 enzyme activity may have important implications for drug safety/efficacy and cancer susceptibility. Because the epigenetic factors and ASE can lead to phenotypic variability in the pharmacodynamic and pharmacokinetic outcomes of drug therapy, we considered it of interest to investigate the function of DNA methylation and differential allelic expression in CYP1A2 gene regulation as determinants of interindividual variation in total CYP1A2 mRNA expression and enzyme activity. The results indicate the importance of two core methylation CpG sites located near the transcription start site to be associated with variations in the total CYP1A2 transcript level and differential allelic expression phenotype (Figure 1 ).
Results

Detection of ASE in CYP1A2
A total of 65 human liver samples were genotyped for the marker SNP rs2470890 and of those 23 were found to be heterozygous for this SNP. The regions encompassing the rs2470890 were PCR amplified from both genomic DNA (gDNA) and mRNA (after conversion to cDNA), followed by minisequencing analysis of each allele. PCR testing for gDNA and cDNA samples was carried out using the same conditions for all fragments, and the amplicon size was verified by agarose gel electrophoresis. The averages of the signal fraction (S Allele1 /(S Allele1 þ S Allele2 )) from the cDNA were compared with the signal fraction from the respective gDNA as a reference to determine the presence of differential allelic expression. Of the 23 heterozygous liver samples, 11 (47.8%) displayed significant differences in their allelic expression (Po0.05, Figure 2 ). There was no correlation in these samples between the total mRNA expression level and allelic expression ratio or ASE phenotype.
DNA methylation frequency in human livers and hepatic CYP1A2 mRNA expression The region covering the CpG island ( Figure 3 ) was PCR amplified from gDNA after bisulfite treatment. DNA methylation frequency was determined by pyrosequencing using six internal sequencing primers that cover overlapping regions. Complete data concerning the DNA methylation frequencies and mRNA quantification were obtained from 48 human livers. Analysis of the methylation pattern revealed two domains with region-specific differences in the distribution and level of CpG methylation. The first domain (domain 1) contained CpG sites 5, 6, 7, 13, 17, 18 and 19 , and the second domain (domain 2) consisted of CpG sites 8, 9, 10, 11, 12, 14, 15, 16, 17 and 21 . CpG site 17 was common for both domains (Figure 3) .
The distribution of the methylation frequency pattern and level of variation in the whole CpG island, domain 1, domain 2 and CpG sites 14 and 16 in relation to the hepatic CYP1A2 mRNA expression is shown in Table 1 . We found a significant negative correlation between the overall mean methylation frequency of the 17 CpG sites and total CYP1A2 mRNA expression (P ¼ 0.018); thus, a lower extent of methylation associated to a higher CYP1A2 mRNA expression level. The mean methylation frequencies of domain 2 correlated significantly with the total CYP1A2 mRNA levels (P ¼ 0.02), but there was no correlation between the mRNA levels and the methylation of domain 1 (P ¼ 0.18). We further compared the CYP1A2 mRNA levels with the mean methylation frequency of each CpG site within domain 2. The highest negative correlation was found for the CpG sites 14 (P ¼ 0.006) and 16 (P ¼ 0.009), located in middle of domain 2, whereas no correlation was found with the other CpG sites.
Association of methylation frequency with ASE
There was no significant correlation between the overall mean methylation frequency of the 17 CpG sites with ASE phenotype in the 23 human livers used in this study (P ¼ 0.11). Considering the methylation frequency of the two domains separately, no correlation was found with domain 1 but a borderline correlation with mean methylation frequency of domain 2 was observed (P ¼ 0.054). We further analyzed associations between the mean methylation frequencies of each individual CpG site located in domain 2 with the ASE phenotype. The result indicated a significant correlation between the mean methylation frequency of CpG sites 9 (r 2 ¼ 0.21, P ¼ 0.04) and 11 (r 2 ¼ 0.33, P ¼ 0.006) located in the upper region of domain 2 with ASE phenotype in that a lower methylation frequency predicted a higher variation in the relative transcript level derived from the two alleles. Neither the methylation frequency at CpG sites 9 and 11 nor the ASE phenotype correlated with the total hepatic CYP1A2 mRNA levels. Correlations between CYP1A2 mRNA expression, protein content and enzyme activity CYP1A2 enzyme activity was measured in the 21 human livers using 3 different probes, caffeine, phenacetin and 7-ethoxyresorufin (EROD). There were significant correlations in CYP1A2 enzyme activity determination between the three probes: caffeine vs EROD (Po0.0001, r 2 ¼ 0.75), caffeine vs phenacetin (P ¼ 0.0001, r 2 ¼ 0.86) and phenacetin vs EROD (Po0.0001, r 2 ¼ 0.86). The enzyme activity using caffeine, EROD and phenacetin was correlated significantly with mean CYP1A2 mRNA level (P ¼ 0.035, P ¼ 0.015 and P ¼ 0.029, respectively) and protein content (Po0.0001 for all three probes). There were no significant correlations between mRNA level and protein content (P ¼ 0.16, statistical power ¼ 28.0%, using a two-sided test and a set at 0.05).
Correlations of CYP1A2 genotype with CYP1A2 phenotype, ASE and DNA methylation frequency To investigate linkage of the marker SNP rs2470890 with other known CYP1A2 SNPs that may have influence on the mRNA expression, we genotyped the livers for the known CYP1A2 variants (À3858 G4A, À2467 delT, À739T4G, À729 C4T and À163 C4A). The SNP frequencies of À3860G4A, À2467delT, À163C4A and rs2470890 were 5.0, 5.0, 67.5 and 62.5%, respectively. CYP1A2*1K (À729C4T and À739T4G) was not detected. Linkage analysis using Arlequin population genetics software indicated significant linkage of rs2470890 with À163C4A occurring at a frequency of 62.5% but not with the other SNPs. However, none of the individual CYP1A2 SNPs/ haplotypes including the haplotype comprising the marker SNP rs2470890 and À163C4A showed any significant correlation with CYP1A2 mRNA expression level, protein content, enzyme activity as determined by three different probes (caffeine, EROD and phenacetin), ASE or variations in DNA methylation frequencies in human livers.
Discussion
We investigated the function of gene methylation and differential allelic expression in CYP1A2 gene regulation with the aim to understand the molecular basis behind the observed wide variation in CYP1A2 gene expression in human liver. The results indicated ASE of the CYP1A2 gene that is independent of the total CYP1A2 mRNA expression. We were furthermore able to identify two independent core methylation sites located close to the translation start site as determinants of interindividual variation in the CYP1A2 mRNA levels and ASE phenotype, respectively, presenting an additional insight into the regulation of CYP1A2 gene to cause altered expression and enzyme activity in humans.
We investigated whether the marker SNP (rs2470890) used in the ASE and DNA methylation analysis is in linkage disequilibrium with other known CYP1A2 SNPs that might influence the mRNA expression and enzyme activity. Indeed, the rs2470890 was linked to À163C4A. However, none of the individual SNPs/haplotypes including the marker SNP plus À163C4A haplotype had significant influences on mRNA expression, protein content, enzyme activity, differential expression of the alleles or variations in DNA methylation frequencies in human livers. Recently, we reported that none of the CYP1A2 SNPs/haplotypes investigated for affected enzyme activity using caffeine as a probe in Swedish and Korean populations. 12 Accordingly, sequencing of the CYP1A1_CYP1A2 locus of the highest and lowest CYP1A2 subjects worldwide, who have previously been CYP1A2 phenotyped, revealed that no SNP or haplotype in the CYP1A2 gene has yet been identified that can unequivocally be used to predict the metabolic phenotype. 11 Lack of CYP1A2 the observed genotypephenotype relationship was indeed the basis for the present study; that is, searching for additional factors such as epigenetic that may influence interindividual variations in CYP1A2 expression level in human livers.
The CYP1A2 gene is specifically expressed in the liver why analysis of ASE and gene methylation was analyzed in 65 different human liver samples. About half of the livers investigated by the ASE assay displayed significant variation in the levels of transcript derived from the two alleles. Some genes that display ASE are present on chromosomes that contain other imprinted genes, 16 which is also warrant for the CYP1A2 gene on chromosome 15 where other imprinted genes in the region are present. [27] [28] [29] We found no significant correlation between ASE and total CYP1A2 gene expression at the mRNA level. Differential allelic expression is influenced mainly by cis-acting mechanisms affecting gene regulation and/or mRNA processing, whereas total gene expression is influenced by both cisand trans-acting factors. Measuring the relative allelic mRNA expression level selectively detects cis-acting factors and/or epigenetic factors. 30, 31 Consequently, the observed differences between ASE and CYP1A2 gene expression levels indicate that the CYP1A2 gene is also regulated by transacting mechanisms that differ between individuals.
As indicated in Figure 2 , the preferably expressed CYP1A2 allele varied between livers and this bidirectional ASE could result from allelic heterogeneity of one or more cis-acting regulatory polymorphisms present in coding, intronic and/ or other noncoding regulatory sequences, 32 or from DNA methylation, histone acetylation and other epigenetic factors. 16, 33 Alternatively, the marker SNP used in the ASE screen could be in linkage disequilibrium to another SNP that is responsible for the differential expression of allelic transcripts, but that does not show unidirectional ASE due to noncomplete linkage disequilibrium with the marker SNP.
We used the Pyrosequencing technology that is ideally suited for the simultaneous analysis and quantification of the methylation degree of several CpG positions in proximity. The results indicate that the overall DNA methylation frequency of the 17 CpG sites in the CpG island located close to the translation start site in exon 2 most likely determine individual variation in total CYP1A2 mRNA expression levels in human livers.
Previous studies indicated that a group of non-X-linked bona fide promoter CpG islands are densely methylated in normal somatic tissues and that DNA methylation has an important function in silencing germ-cell-specific genes in somatic cells. 34 Thus, we evaluated the effect of DNA methylation on CYP1A2 gene expression and investigated whether demethylation alleviates the silencing pressure to increase gene expression in human B16A2 cell lines. Hepatoma B1A2 cells were treated with increasing concentrations of a hypomethylating agent AzaC and relative quantification of CYP1A2 mRNA by RT-PCR revealed a linear raise in CYP1A2 gene expression with increasing concentration of AzaC, illustrating that DNA methylation is involved in the repression of CYP1A2 (Figure 4) .
Comparison of mean methylation frequency of each CpG site within domain 2, where methylation primarily correlated to CYP1A2 mRNA levels, indicated significant correlation with CpG sites 14 and 16 (located in the middle of domain 2) whereas no association was found with other CpG sites. This may indicate that CpG sites 14 and 16, as core methylation regulatory sites, are of importance in determining variations in CYP1A2 gene expression. Interestingly, the level of and variance in the methylation frequency among the human livers was the highest for CpG sites 14 and 16 compared to the other CpG sites in the island (Table 2) . Table 1 Summary of sequencing primers, number of CpGs, sequencing length and dispensation order used for sequencing of CpG island in CYP1A2 exon 2
Sequencing primers
Number of CpGs Sequence length Dispensation order ASE and gene methylation of CYP1A2
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Previous studies presented evidence for variation in the degree of methylation as a cause for differential allelic expression. 16, 17, 20, 31 In the present study, although ASE phenotype did not correlate significantly with the overall methylation frequency of the CpG island, region-specific comparison of methylation frequencies indicated a significant correlation between the methylation frequency of CpG sites 9 and 11 (located in the upstream region of domain 2) with the ASE phenotype. Thus, a lower methylation frequency indicated a higher ASE phenotype. This indicates that in the absence of a silencing pressure from gene methylation, the cis-acting factor responsible for the ASE phenotype exerts its effect. It is interesting to note that similar to the ASE phenotype, methylation frequency of CpG sites 9 and 11 was also not associated with the total CYP1A2 mRNA expression level. This indicates that although methylation frequency at CpG sites 9 and 11 may contribute to the presence of differential allelic expression, CYP1A2 mRNA expression levels are probably influenced to a major extent by the degree of methylation of the whole CpG island, mainly at the CpG sites 14 and 16. Hammons et al. 25 reported the function of a single sitespecific DNA methylation status of the CCGG site (bp À2759) located adjacent to an AP-1 site to be responsible for the interindividual variation of CYP1A2. This site, not any other place 5 kb upstream of the gene, could however be identified by us as a CpG site in a CpG island. Instead, we found a CpG island containing 17 CpG sites, located close to the translation start site, and considered it of importance to investigate further.
Silencing of one of the X chromosomes in females and allelic imprinting or monoallelic expression, depending on parental origin, is highly regulated through gene methylation reprogramming that may occur in germ cells and during gametogenesis. 35, 36 However, the function of CpG methylation in nonimprinted, monoallelic expressing genes is not yet fully explored. The two identified core methylation sites are located in the same domain close to each other but apparently having two different functions: the upper region determines the ASE phenotype and the middle region determines the total CYP1A2 mRNA expression. Searching for transcription binding sites in the CpG island, we found that both core methylation sites are surrounded by transcription binding sites for transcription factors such as BRAC1, TFAP3A, SP1, SPI1, GATA-2 and GATA-3. Given the fact that CYP1A2 is a hepatic P450, we found that variation in the methylation frequency of the binding sites and hence blocking access to transcription factors might be important in controlling the level of hepatic CYP1A2 gene expression. It is also of interest to note that the aryl hydrocarbon receptor (AhR) binding site is located close to the CpG island ( Figure 3 ) and thus variation in degree of gene methylation might also result in differential CYP1A2 inducibility.
Methylation patterns may be cell type and/or tissue specific and change slowly with age and in response to environmental effects such as diet. 37, 38 Variation in methylation frequency due to dietary related or environmental factors may be important in determining the observed wide ethnic variation in CYP1A2 enzyme activity between whites and Asians. 12 Furthermore, previous pedigree studies demonstrated heritability of ASE being transmitted by Mendelian inheritance. 17, 39 Gene methylation patterns in somatic differentiated cells are also generally stable and heritable. 35 Inheritance of ASE in the CYP3A4 gene expression has been previously reported. 22 Accordingly the observed ASE in CYP1A2 gene expression may be inherited to cause variation in enzyme activity similar to genetic polymorphisms. Several studies reported lack of genotype-phenotype relationship in CYP1A2. Our study explains the molecular mechanism behind variations in CYP1A2 gene expression and genotype-phenotype concordance to a certain extent. The magnitude of ASE as well as methylation frequency varies between individuals and possibly affects enzyme activity and treatment response.
In conclusion, our study demonstrates that CYP1A2 gene expression displays ASE and is influenced by DNA methylation. We showed that only a few CpG sites and quite small regions of the CpG island provide relevant information for differential methylation analysis. The present study has given a new insight into the regulation of CYP1A2. However, further investigations are needed to explore the exact mechanisms involved in ASE, transregulatory mechanisms and DNA methylation in explaining interindividual and ethnic variability in CYP1A2 expression. ASE discovery List of CpG sites located in domains 1 and 2 is described in Figure 3 .
ASE and gene methylation of CYP1A2
coupled with elucidation of the underlying mechanisms may provide a comprehensive view of transcriptional regulation as well as functional markers for drug metabolizing genes (for example, CYP1A2 and CYP3A4) where genetic polymorphisms have a minor function in explaining the observed wide interindividual and ethnic variability in enzyme activity.
Materials and methods
Study samples
A total of 65 unrelated healthy human livers of Scandinavian origin belonging to a donor liver biobank, established at the Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Sweden, were utilized for this study after approval from the ethics committee at Karolinska Institutet. Tissue for preparation of microsomes was only available from 21 human livers.
Preparation of genomic DNA and cDNA Genomic DNA and total RNA were isolated from the liver samples using QIAamp DNA Mini Kit and RNeasy Mini Kit (Qiagen, Hilden, Germany), respectively. Total RNA was treated with RNase-free DNase (Promega, Madison, WI, USA) to remove any contamination from gDNA during total RNA preparation. cDNA was synthesized using the First Strand cDNA Synthesis Kit (Fermentas, Burlington, Ontario, Canada), following the manufacturer's instructions using 2 mg of total RNA. cDNA was prepared from each liver using random hexamer and oligo (dT) 18 primer.
Detection of differential allelic expression by Tag array minisequencing Assay design. Several SNPs in the CYP1A2 gene were considered as candidate markers for the ASE assay. Selection criteria for a marker SNP were high minor allele frequency with no significant effect on enzyme expression level or enzyme activity and location in the transcribed coding region so that the same set of primers for PCR amplification can be used in both gDNA and mRNA. A nonfunctional silent SNP (5347T4C, rs2470890) located in exon 7 of the CYP1A2 gene was selected as marker. Previously we identified this SNP (rs2470890) in Ethiopians and reported lack of influence on CYP1A2 enzyme activity using caffeine as a probe. 13 To examine linkage of the marker SNP with other CYP1A2 SNPs, we genotyped livers for known CYP1A2 variant SNPs (À3858G4A, À2467delT, À739T4G, À729C4T, À163C4A) as described previously. 12 PCR primers and minisequencing primers with 5 0 tag sequences covering the marker SNP site were designed using the Autoprimer (http://www.autoprimer.com; Beckman Coulter) software. The primers were obtained from Integrated DNA Technologies (Coralville, IA, USA).
PCR minisequencing and hybridization. Genomic DNA and cDNA were used for genotyping of the marker SNP using 4 ng DNA by minisequencing analysis as described previously. 30, 40 In brief a 164-bp PCR fragment spanning the marker SNP site was amplified by PCR using a forward primer (5 0 -ATGAAGCACGCCCGCTGT-3 0 ) and a reverse primer (5 0 -TTGGCTAAAGCTGCTATTTTTTA-3 0 ) from both gDNA and cDNA. To remove remaining dNTPs and primers, we treated the PCR products (7.2 ml) with 1 U ml À1 shrimp alkaline phosphatase and 0.48 U ml À1 exonuclease I (USB Corporation, Cleveland, OH, USA). The oligonucleotides complementary to the tag sequence attached to the 5 0 -end of the minisequencing primer (5 0 -AATACGCTGAATAG AGCCCTAGGCGCGGCTGCGCTTCTCCATCAA-3 0 ) were immobilized on the CodeLink Activated Slides (GE Healthcare, Uppsala, Sweden) in duplicate spots in each subarray. Cyclic minisequencing of the PCR products from both gDNA and cDNA, hybridization of the minisequencing reaction products to the captured oligonucleotides (cTags) on the slides and washing of the slides were performed as described previously. 41 Each sample (DNA and the corresponding cDNA) was run in triplicates on the same slide.
Signal detection and data analysis. Fluorescence signals from the microarrays were measured using a ScanArray Express instrument (PerkinElmer Life Sciences, Boston, MA, USA). The laser power was kept constant at 80% and the photomultiplier tube gain adjusted to obtain equal signal levels from the reaction control spots in all four-laser channels. The excitation lasers were Blue Argon 488 nm for R110, green HeNe 543.8 nm for Tamra, yellow HeNe 594 nm for Texas Red and red HeNe 632.8 nm for Cy5. The signal intensities were determined with the QuantArray analysis 3.1 software (PerkinElmer Life Sciences). The SNP genotype were assigned using the SNPSnapper software version 3.0.0.191 (http://www.bioinfo.helsinki.fi/SNPsnapper/) based on scatter plots with the logarithm of the sum of both fluorescence signals (S Allele1 þ S Allele2 ) on the vertical axis and the fluorescence signal fractions (S Allele1 /(S Allele1 þ S Allele2 )) on the horizontal axis. ASE for each heterozygous individual was determined by calculating the fluorescence signal between the two alleles (S Allele1 /(S Allele1 þ S Allele2 )) in both cDNA and the respective gDNA as a reference for each heterozygous liver sample. The mean signal intensity of the duplicate spots run in triplicates on one subarray was considered as one replicate assay.
Determination of DNA methylation frequency by pyrosequencing Assay design. Searching for CpG islands in the CYP1A2 gene covering up to 5000 bp upstream region from the translation start codon was carried out using Methyl Primer Express software (Applied Biosystems, Foster City, CA, USA). We found one CpG island close to the transcription start site in exon 2. Seventeen of the CpG sites located in the center of the island were selected for DNA methylation frequency analysis (Figure 1 ).
Bisulfite treatment and PCR
The gDNA isolated from human liver samples was treated with sodium bisulfite using the EZ DNA Methylation Kit (Zymo Research Corporation, Orange, CA, USA). PCR primers were designed to amplify the CpG island containing 17 CpG sites located in exon 2. A 309-bp region spanning the island was amplified by PCR from bisulfate-treated gDNA samples. The PCR mix contained 2.5 ml 10 Â PCR buffer, 0.5 ml 25 mM MgCl 2 solution, 0.125 ml Smart-Taq Hot Thermostable DNA Polymerase (Naxo Ltd., Tartu, Estonia), 0.5 ml 10 mM of forward (5 0 -TTTGGTATTGTTAAGGATGAGT TAG-3 0 ) and biotinylated reverse (5 0 -ACATACTCCTCCAAA TAACAAAAA-3 0 ) primers (Invitrogen, Carlsbad, CA, USA), and 0.5 ml 10 mM dNTP (GE Healthcare), 1 ml bisulfite-treated DNA and sterile water in a final volume of 25 ml. The PCR conditions were initial activation of the Smart-Taq Hot enzyme at 95 1C for 10 min followed by 50 cycles of 95 1C for 30 s, 53 1C for 1 min, 72 1C for 1 min and a final extension at 72 1C for 7 min on a GeneAmp PCR system 2700 (Applied Biosystems). The PCR products were analyzed on a 1.5% agarose gel for quality assurance and verification before pyrosequencing.
Pyrosequencing
The amplified PCR product was analyzed by pyrosequencing using six internal sequencing primers designed to cover all the 17 CpG sites. Sequencing primers, CpG sites and pyrosequencing dispensation orders including internal control for bisulfite treatment are listed in Table 3 . Pyrosequencing was performed on Pyro Q-CpG software (Biotage, Uppsala, Sweden) using the PyroGold SQA Reagent Kit (Biotage) as described previously. 45 The software reports a peak height directly proportional to the number of molecules incorporated into the growing DNA chain.
AzaC treatment and total RNA isolation from cultured cells The human hepatoma cell lines B16A2 were cultured based on ATCC protocols. All cell culture media and supplements were obtained from Invitrogen (Rockville, MD, USA). Cells were treated with AzaC (Sigma-Aldrich, Steinheim, Germany) at varying concentrations (0, 100, 500 and 1000 mM) for 5 days. B16A2 cells were allowed to reach total confluence and maintained at such level for 1 week before AzaC treatment was commenced. Subsequent to AzaC treatments, total RNA was isolated using Trizol reagent (Invitrogen) following manufacturer's recommendations. Reverse transcription was carried out from 5 mg total RNA using the SuperScript II (Invitrogen) system in the presence of the ribonuclease inhibitor RNaseOUT (Invitrogen).
Quantitative real-time PCR
The quantification of the total CYP1A2 mRNA levels from human livers and B16A2 cell lines treated with varying concentrations of AzaC was performed by real-time PCR using 7500 Fast Real-Time PCR system. The quantification mixture contained 7.5 ml of TaqMan 2 Â PCR Master Mix, 0.5 ml of cDNA, 0.75 ml of 20 Â mix of predesigned TaqMan Gene Expressions Assay contained primers for CYP1A2 mRNA spanning sequence boundary between exons 6 and 7 and probe in a final 15 ml volume of reaction. Each sample was ran in triplicates and human 18S rRNA 20 Â was used as endogenous control. The real-time PCR instrument, TaqMan master mix, primers and probe were purchased from Applied Biosystems.
Determination of CYP1A2 enzyme activity in human liver microsomes Microsomes were prepared from 21 human livers bank as described previously. 46 The pellet containing the microsomal fraction was suspended and homogenized in 50 mM potassium phosphate buffer, pH 7.4, to give a final concentration of 30-50 mg microsomal protein per ml and stored at À80 1C until use. The protein content was determined by Lowry method, 47 and the total cytochrome P450 content was quantified. 48 The CYP1A2 enzyme activity was estimated by the using caffeine, EROD and phenacetin as marker probes (Sigma-Aldrich, St Louis, MO, USA). Assay conditions used for CYP1A2 enzyme activity determination in human liver microsomes using the three different probes are summarized in Table 3 . Microsomes were diluted with buffer and preincubated for 3 min at 37 1C before the probe substrate was added. Multiple control incubations were performed with boiled microsomes, without microsomes, without nicotinamide adenine dinucleotide phosphate (NADPH) or by adding stop solution before NADPH. 
CYP1A2 protein content determination
Determination of CYP1A2 protein content was carried out as described previously. 49 In brief, a total of 5 mg protein was separated by SDS-polyacrylamide gel electrophoresis using a 10% gel. After transfer, the Hybond-C extra membrane (Amersham Pharmacia Biotech, Uppsala, Sweden) was blocked in Tris-buffered saline containing 0.05% (v/v) Tween 20 and 5% fat-free milk and incubated with 1:2500 dilution of the primary CYP1A1/CYP1A2 polyclonal antibody (Daiichi Pure Chemicals Co. Ltd., Ibaraki, Japan). This was followed by incubation with a 1:2500 diluted goat antirabbit horseradish peroxidase-conjugated antibody (Pierce, Rockford, IL, USA). Detection was performed using SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Statistics
A two-tailed Student's t-test was used to compare the mean allelic signal (S Allele1 /(S Allele1 þ S Allele2 )) between gDNA and cDNA for each heterozygous liver. Analysis of variance was used to analyze association between CYP1A2 genotype, mRNA expression protein content and enzyme activity, using all three marker probes. Haplotype analysis and estimation of expected haplotype frequencies from the raw genotype data were carried out using population genetic software program Arlequin version 2.000. The Spearman's rank correlation test and regression analysis (after converting to log values) were used to analyze association between mean methylation frequency with ASE phenotype and total mRNA level.
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